Table 2 Prophylactic treatment, angioedema attack frequency and necessity for acute attack treatment at baseline and follow-up
From: High occurrence of antihistamine resistance in patients with recurrent idiopathic angioedema
Baseline (n = 120) | Follow-up (n = 120) | |
|---|---|---|
Prophylactic treatment (%) | ||
Unknown | 3 (3%) | 0 (0%) |
None | 62 (52%) | 18 (15%) |
Antihistamine mono-therapy | 45 (38%) | 87 (73%) |
Onefold daily dose | 27 (23%) | 17 (14%) |
Twofold daily dose | 11 (9%) | 30 (25%) |
Threefold daily dose | 2 (2%) | 7 (6%) |
Fourfold daily dose | 5 (4%) | 21 (18%) |
> Fourfold daily dose | 0 (0%) | 12 (10%) |
Antihistamines + add-on | 7 (6%)a | 15 (13%)c |
Other treatment | 3 (3%)b | 0 (0%) |
Baseline (n = 120) | All n = 120 | No intervention n = 21d | Antihistamines only n = 99 | + Add-on n = 99 | |
|---|---|---|---|---|---|
Attack frequency (%) | |||||
Unknown | 17 (14%) | 15 (13%) | 3 (14%) | 11 (11%) | 12 (12%) |
≥ 1 per week | 42 (35%) | 15 (13%) | 2 (10%) | 17 (17%) | 13 (13%) |
≥ 1 per month | 44 (37%) | 24 (20%) | 4 (19%) | 23 (23%) | 20 (20%) |
≥ 1 per year | 17 (14%) | 30 (25%) | 6 (29%) | 23 (23%) | 24 (24%) |
No attack | 0 (0%) | 36 (30%) | 6 (29%) | 25 (25%) | 30 (30%) |
Baseline (n = 120) | All = 120 | No intervention n = 21 | Antihistamines + add-on n = 99 | |
|---|---|---|---|---|
Acute attack treatment (%)e | ||||
Unknown | 15 (13%) | 18 (15%) | 3 (14%) | 15 (15%) |
None | 11 (9%) | 51 (43%) | 6 (29%) | 45 (45%) |
1. Antihistamines | 25 (21%) | 26 (22%) | 8 (38%) | 18 (18%) |
2. Antihistamines and/or corticosteroids | 14 (12%) | 17 (14%) | 2 (10%) | 16 (16%) |
3. Epipen | 5 (4%) | 3 (3%) | 1 (5%) | 2 (2%) |
4. Urgent care center | 43 (36%) | 5 (4%) | 2 (10%) | 3 (3%) |
5. Hospitalization or Intensive care | 7 (6%) | 0 (0%) | 0 (0%) | 0 (0%) |